Safety and Efficacy of KPI-121 in Subjects With Inflammatory Meibomian Gland Disease

This is a Phase II, multicenter, double-masked, randomized, vehicle-controlled,
parallel-group study designed to evaluate the efficacy and safety of KPI-121 ophthalmic
suspension versus vehicle in subjects with signs and symptoms of inflammatory meibomian
gland disease. The product will be studied over 28 days, with 1-2 drops instilled in each
eye four times daily (QID).

Inclusion Criteria:

Have a documented clinical diagnosis of inflammatory meibeomian gland disease in both
eyes.

Exclusion Criteria:

- Known hypersensitivity/contraindication to study product(s) or components.

- Be currently receiving treatment for glaucoma, have history of or current glaucoma,
or an IOP over 21mmHg at Visit 1 (Screening) or Visit 2 (Randomization).

- Be unwilling to discontinue warm compress therapy, lid expression, or lid massage 14
days prior to Day 1 and for the duration of the study.

- Diagnosis of: ongoing ocular infection; severe/serious ocular condition that in
judgment of Investigator could confound study assessments or limit compliance;
severe/serious systemic disease or uncontrolled medical condition that in judgment of
Investigator could confound study assessments or limit compliance; or have been
exposed to an investigational drug within the 30 days prior to screening.

- Have had ocular surgery in the past 90 days or require ocular surgery during the
study.

- In the opinion of Investigator or study coordinator, be unwilling or unable to comply
with study protocol or unable to successfully instill eye drops.